Mortality and morbidity of Human Metapneumovirus infection in the pre
COVID19 Era, the value of of Charlson Comorbidity Index on outcome
predictions
Abstract
Abstract Introduction: Human metapneumovirus (HMPV)
was recently recognized as an important cause of seasonal respiratory
tract infections mainly in children and immunocompromised adults. The
use of Charlson Comorbity index (CCI) to predict outcome in hospitalized
patients has been validated in several settings. Objective:
Describe the clinical characteristics of adult patients with HMPV
infection, evaluate the value to the CCI in predicting outcome.
Methods: Single center retrospective chart review study of
hospitalized patients with HMPV infection in 2017. Results: 22
adult patients with a mean age of 65 years were reviewed. The mean CCI
was 4.6±2.6. The overall mortality was 22%. Abnormal chest radiograph
(CXR) was reported in 15 patients. CCI was not different between
survivors and non survivors. Non survivors were more likely to have
abnormal CXR and higher fever at the time of diagnosis, required
mechanical ventilation or were treated for other concomitant infections.
Conclusion: The average of CCI was 4.5 which was not
significantly different between survivors and non survivors. Mortality
rate was elevated at 22% and is likely associated with admission to the
ICU and presence of another concomitant infection.